Nvidia CEO Jensen Huang is out amid a scandal involving two alleged affairs, including one with a woman suspected of spying for China and the other who was a VP of the company’s healthcare division.The AI chip giant named CFO Colette Kress interim CEO as it investigates potential national security implications, while Huang’s abrupt departure sent Nvidia shares tumbling. (The New York Times)
Drugmakers tap China AI app boom to reach doctors as crackdown upends marketing.A multiyear drive to root out bribery and corruption in the healthcare sector gathered pace this summer. (Reuters)
The Food and Drug Administration’s fast-track drug review experiment appears to have hit the brakes.The agency has effectively shelved its Commissioner’s National Priority Voucher program, which promised to cut some drug reviews to as little as one or two months, after former commissioner Marty Makary’s departure in May, according to six sources and internal documents reviewed by Reuters. (The Independent)
How Hims plans to reinvigorate its business.Hims & Hers, once obsessed with delivering “personalized care” through compounded drug products, is now banking on brand-name treatments and the pharmaceutical giants it previously sparred with. (Endpoints News)
Doctors and scientists are headed to Congress, but rebuilding trust in science is another story.Candidates backed by the pro-science group 314 Action flipped 10 congressional seats in the midterms, giving Democrats new voices to challenge HHS Secretary Robert F. Kennedy Jr.’s public health policies, though experts warn that turning vaccine skepticism into another partisan fight could further erode public confidence. (STAT News)
To read yesterday’s edition of Five things for pharma marketers to know, click here.
